SCHEMBL3604598

SCHEMBL3604598

CCOC(=O)C(O)(c1cn(Cc2ccccc2)c2cc(NS(=O)(=O)c3ccc(C)cc3)ccc12)C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
TP53 P04637 1/20 0.43
THRB P10828 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 4/20 0.42
SERPINE1 P05121 1/20 0.42
LMNA P02545 3/20 0.41
KDM4E B2RXH2 2/20 0.41
CYP1A2 P05177 1/20 0.41
POLB P06746 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTT P42858 1/20 0.41
HSD17B10 Q99714 2/20 0.41
RECQL P46063 1/20 0.41
NR1I2 O75469 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3592376 0.94 MAPT (0.46) MAPTSMN1; SMN2TP53THRBMEN1
SCHEMBL3598788 0.90 P2RX3 (0.43) MAPTTHRBMEN1KMT2ASERPINE1
SCHEMBL3589822 0.85 MAPT (0.47) MAPTSMN1; SMN2TP53THRBMEN1
SCHEMBL3593361 0.85 PTPN1 (0.47) MAPTSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL3588733 0.84 MAPK1 (0.42) MAPTTP53SERPINE1P2RX3
SCHEMBL3600722 0.84 LMNA (0.44) MAPTSMN1; SMN2MEN1KMT2ALMNA
SCHEMBL3600338 0.81 GLA (0.43) MEN1KMT2AALDH1A1SERPINE1POLB
SCHEMBL3600671 0.81 PTPN1 (0.47) MAPTSMN1; SMN2KMT2AALDH1A1SERPINE1
SCHEMBL13254016 0.81 PTPN1 (0.47) MAPTSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL3602094 0.81 GLA (0.42) THRBSERPINE1POLBP2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
EP-1930320-A1 NOVEL FUSED PYRROLE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-06-11 EP disclosed
EP-1930320-A1 NOVEL FUSED PYRROLE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE NR3C1, NR3C2, NR0B1 MAPT 4708/4885SMN1; SMN2 4722/4885TP53 3579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.